Benefits of fixed-doses combination for type 2 diabetes
10.3760/cma.j.issn.1000-6699.2010.07.032
- VernacularTitle:复方降糖制剂的获益
- Author:
Lulu CHEN
- Publication Type:Journal Article
- Keywords:
Metformin;
Rosiglitazone;
Fasting blood glucose;
Postprandial blood glucose;
Insulin resistence;
Hypoglycemia
- From:
Chinese Journal of Endocrinology and Metabolism
2010;26(7):-
- CountryChina
- Language:Chinese
-
Abstract:
With consideration of optimizing treatment of type 2 diabetes,early combination therapy has been deeply explored, with fixed-doses combination therapy as a available preparation for easier administration. Avandamet ( rosiglitazone maleate and metformin HC1) is widely used in clinical treatment, providing comprehensive and sustained long-term efficacy and confirmed safety with lower hypoglycemia risk, and also high convenience and compliance. Combination of rosiglitazone and metformin improves the dual core defects of type 2 diabetes, targeting FPG and PPG reduction through decreasing hepatic glucose output, and improving peripheral insulin resistance, especially increasing skeletal muscle's utilization of glucose respectively. Large-scale clinical trials gave more confidence to Avandamet. Recently, RECORD study indicated that rosiglitazone in combination with metformin achieved long-term antihyperglycemic efficacy in 5 years period, superior to sulphanylureas plus metformin. Additionally, lower risk of hypoglycemia is another benefit of Avandamet. In conclusion,early use of Avandamet can yield much more benefits than monotherapy and late administration, in consistent with implication of evidence-based trial, guideline, and clinical experiences.
